2023 Sales of Major Oncology Medicines
Global spending on cancer medicines reached $223B in 2023, according to IQVIA. Here's a look at major oncology medicines and some insights behind the numbers: [Source]
1. Several top sellers face US exclusivity milestones. Pfizer's basic US Ibrance patent extends to March 2027. In its 2023 annual report, Merck expected US market exclusivity for Keytruda to end in 2028; BMS listed 2028 as Opdivo's estimated minimum US market-exclusivity date. These are US dates, not simultaneous worldwide expirations or guaranteed competitor launch dates. [Source] [Source] [Source]
2. Five of the reported product lines gained more than $1B each compared with 2022: Keytruda rose $4.074B, Darzalex $1.767B, AstraZeneca's combined Imfinzi/Imjudo line $1.453B, Verzenio $1.380B, and Enhertu's combined Daiichi Sankyo and AstraZeneca sales $1.313B. The $4.237B Imfinzi/Imjudo total includes $218M from Imjudo, so it should not be labeled as Imfinzi alone. [Source] [Source] [Source] [Source]
BMS's Revlimid fell $3.881B, from $9.978B in 2022 to $6.097B in 2023. BMS attributed the decline primarily to generic competition and an increase in patients receiving free drug through its patient-assistance foundation. [Source] [Source]
3. The US accounted for a large share of these companies' reported sales: 54.2% for J&J's Darzalex ($5.277B of $9.744B), 58.6% for BMS's Opdivo ($5.283B of $9.009B), and 66.3% for Pfizer's Ibrance ($3.151B of $4.753B). BMS's figures include Puerto Rico in the US. The Opdivo percentage uses BMS's reported revenue, not a combined total with Ono's separately reported territories. [Source] [Source] [Source]
The next few years bring major exclusivity milestones alongside investment in new modalities. IQVIA reported that the number of ADC trials grew 26% from 2022 to 2023. For portfolio planning, the sales figures show which established brands generated revenue while companies developed the next wave of treatments. [Source]
Sales definitions: Imbruvica's 2023 product sales totaled $4.879B: AbbVie's $2.665B in US sales plus J&J's $2.214B outside the US. Adding J&J's US collaboration revenue or AbbVie's international profit share would count revenue from the same underlying sales twice. [Source] [Source] [Source]
Astellas reported ¥709.3B of Xtandi sales for calendar 2023, combining January–March 2023 with April–December 2023. That is approximately $5.057B at the 2023 average daily exchange rate. Pfizer's Xtandi alliance revenue is excluded from this total. [Source] [Source]
Roche reported Perjeta sales of CHF3.768B and Tecentriq sales of CHF3.766B, equivalent to approximately $4.194B and $4.191B. These conversions use the arithmetic mean of daily 2023 ECB cross-rates: $1.112979 per CHF and $0.007129799 per yen. [Source] [Source]
Enhertu generated $2.566B in combined product sales recorded by Daiichi Sankyo and AstraZeneca. AstraZeneca's $1.022B of Enhertu alliance revenue is excluded to avoid double counting. [Source]
Jakafi/Jakavi, the oral ruxolitinib brands, generated $4.314B in combined 2023 product sales: Incyte's $2.594B in the US plus Novartis's $1.720B outside the US. Incyte's $367.6M of Jakavi royalty revenue is excluded because it derives from the same Novartis sales. These brand totals include graft-versus-host disease as well as myelofibrosis and polycythemia vera; they are not cancer-only indication revenue. Opzelura cream is excluded. [Source] [Source]
Opdivo is shown at BMS’s $9.009B in reported revenue. This excludes Ono’s separately reported territories. Ono’s Japan shipment figures use a different reporting basis, so they are not added to BMS’s net revenue. The comparison therefore identifies reporting scope rather than presenting these values as a uniform worldwide sales ranking. BMS reporting scope
